Research Topics
| Thomas M PisanskySummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinomaThomas M Pisansky
Division of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer 95:513-9. 2002..Predictive models based on pretherapy factors may be useful to estimate the likelihood for clinically relevant extraprostatic disease and may be incorporated into selection criteria for this procedure...- Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppressionMatthew C Solhjem
Division of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer J 10:343-8. 2004..9]) for the NHT group and 1.21 +/- 0.03 (range, 0.8-1.9) for the non-NHT group (P = 0.5). CONCLUSIONS: Prostate volume decreased by approximately one third after 4 months of NHT. NHT did not affect the degree of post-PPB prostatic edema... 
Late toxicity after postprostatectomy salvage radiation therapyJENNIFER L PETERSON
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
Radiother Oncol 93:203-6. 2009..To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP)...- Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithmBrian J Davis
Division of Radiation Oncology, Mayo Clinic and Foundation, 200 First Street, SW Rochester, MN 55905, USA
Brachytherapy 3:106-12. 2004..Routine permanent prostate brachytherapy (PPB) includes CT-based postimplant dosimetry (PID). A method of identifying different source types from CT data in the same implant volume is described... - Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapyMatthew C Solhjem
Division of Radiation Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 60:767-76. 2004..These data are relevant for establishing accuracy in image-fusion based approaches being investigated for real-time intraoperative PPB dosimetry... - Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migrationJeffrey S Eshleman
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 59:419-25. 2004..Nonetheless, the small proportion of implanted seeds that migrated (<or=1%) is highly unlikely to have significant dosimetric consequences... - External beam radiotherapy as curative treatment of prostate cancerThomas M Pisansky
Division of Radiation Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 80:883-98. 2005.... - Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapyNataliya Kovalchuk
Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Brachytherapy 11:111-8. 2012..To quantify the dosimetric deviations that would arise from delivering subsequent prostate high-dose-rate fractions with only needle readjustment and no replanning after the first fraction... - Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinomaChristopher L Hallemeier
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
Int J Radiat Oncol Biol Phys 82:1938-43. 2012.... - High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancerThomas M Pisansky
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 83:1364-72. 2008.... - Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomyRichard Choo
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
BJU Int 98:773-6. 2006 - Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imagingJohn M Schallenkamp
Division of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 63:800-11. 2005..Fiducial markers are stable within the prostate and allow significant margin reduction when used for on-line localization of the prostate... - Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysisJohnny Ray Bernard
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
Int J Radiat Oncol Biol Phys 76:735-40. 2010.... - Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapyDavid J Schwartz
Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Brachytherapy 2:98-102. 2003..Treating radiation oncologists were exposed to less than 20 mSv per 100 cases, significantly less than other fluoroscopically guided procedures. Nonetheless, appropriate radiation exposure precautions during TIPPB should continue... - Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging deviceMichael G Herman
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 57:1131-40. 2003..To develop a real-time electronic portal imaging device (EPID) procedure to identify intraprostatic gold markers and correct daily variations in target position during external beam radiotherapy for prostate cancer... - Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancerThomas M Pisansky
Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
Urology 62:36-45. 2003..The historical precedent for combining androgen suppression with radiotherapy is described, as are the results of prior definitive trials and ongoing studies in this setting... - External-beam radiotherapy for localized prostate cancerThomas M Pisansky
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
N Engl J Med 355:1583-91. 2006 - Patient-specific daily pretreatment setup protocol using electronic portal imaging for radiation therapyMichael H Wittmer
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
J Appl Clin Med Phys 6:1-13. 2005..This procedure resulted in a reduction in setup displacement that was statistically significant, clinically relevant, and approached that of a more typical patient group... - Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancerAlexander S Parker
College of Medicine, Mayo Clinic Florida, Jacksonville, FL 32224, USA
Int J Radiat Oncol Biol Phys 75:1364-70. 2009..Herein, we evaluate the ability of Ki-67 staining in primary prostate cancer to independently aid in the prediction of BCR among men undergoing SRT... 
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831Michele Y Halyard
Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
J Clin Oncol 27:2638-44. 2009..To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy...- Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring systemSteven J Buskirk
Department of Radiation Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
J Urol 176:985-90. 2006..This study was performed to evaluate the results and prognostic factors associated with radiotherapy for a detectable serum prostate specific antigen level after radical prostatectomy... - Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancerBrian J Davis
Division of Radiation Oncology and Department of Urology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Curr Opin Urol 13:117-22. 2003..The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject... - Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancerEdith A Perez
Mayo Clinic, Jacksonville, FL 32224, USA
J Clin Oncol 29:4491-7. 2011.... - Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52James N Ingle
Mayo Clinic and Mayo Foundation, Rochester, MN, USA
Breast Cancer Res Treat 98:217-22. 2006.... - Electronic and film portal images: a comparison of landmark visibility and review accuracyJon J Kruse
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 54:584-91. 2002..5 mm in film, compared to 1.5 mm with SLIC-EPID and 1.3 mm with aSi-EPID. CONCLUSIONS: Both EPIDs are clinically viable replacements for film, but aSi-EPID represents a significant advancement in image quality over film... - Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
J Clin Oncol 25:2035-41. 2007..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence... - Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapyMary Feng
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
Int J Radiat Oncol Biol Phys 68:1417-23. 2007..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities... - Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failureMichael E Ray
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0010, USA
Urology 68:1257-62. 2006..To determine whether nadir prostate-specific antigen (PSA) levels within 12 months (nadir PSA12) after completion of radiotherapy (RT) can be used as an early marker of recurrence risk... - Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantationMichael J Zelefsky
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 67:327-33. 2007..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival... - Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysisEric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Cancer 107:1496-502. 2006.... - Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or lessBernard Fisher
National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
J Clin Oncol 20:4141-9. 2002.... - Comparison of biochemical failure definitions for permanent prostate brachytherapyDeborah A Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 65:1487-93. 2006..To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy... - Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA eraDeborah A Kuban
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Int J Radiat Oncol Biol Phys 57:915-28. 2003..To report the long-term outcome for patients with Stage T1-T2 adenocarcinoma of the prostate definitively irradiated in the prostate-specific antigen (PSA) era... - Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
N Engl J Med 349:17-26. 2003..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse... - PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysisMichael E Ray
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
Int J Radiat Oncol Biol Phys 64:1140-50. 2006.... - INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapyBruce D Minsky
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:1167-74. 2002..To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer... - Morbidity after brachytherapy for prostate adenocarcinomaThomas M Pisansky
Mayo Clin Proc 79:946-7; author reply 947-9. 2004 - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.).. - Long-term follow-up of radiotherapy for prostate cancerThomas M Pisansky
Int J Radiat Oncol Biol Phys 60:1663-4; author repply 1664. 2004 - Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05Steven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 62:956-64. 2005..To prospectively assess health-related quality of life (HRQOL) during the first year after treatment with prostate brachytherapy (PB) alone for T1c-2a prostate cancer... - Increasing external beam dose for T1-T2 prostate cancer: effect on risk groupsHoward D Thames
Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Department of Radiation Oncology, William Beaumont Hospital, Deroit, MI, USA
Int J Radiat Oncol Biol Phys 65:975-81. 2006.... - Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysisEric M Horwitz
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
J Urol 173:797-802. 2005..In this report we determined the sensitivity and specificity of several BF definitions using distant failure (DF) alone or clinical failure (CF), defined as local failure (LF) and/or DF... - Advanced prostate cancer and postoperative radiotherapyThomas M Pisansky
JAMA 297:950-1; author reply 951. 2007